Top Highlights From the 2015 European Cancer Congress

Slideshow

This slide show features some of the top highlights on neuroendocrine tumors, breast cancer, and renal cell carcinoma to come out of the 2015 European Cancer Congress in Vienna.

References:

1. Yao JC, Fazio N, Singh S, et al. Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, phase 3 RADIANT-4 study. Presented at the 2015 European Cancer Congress; Abstract 5LBA.

2. Brastianos PK, Carter S, Santagata S, et al. Genomic characterization of brain metastases and paired primary tumors reveals branched evolution and potential therapeutic targets. Presented at the 2015 European Cancer Congress; Abstract 2905.

3. Choueiri T, Escudier B, Powles T, et al. Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial. Presented at the 2015 European Cancer Congress; Abstract 4LBA.

4. Van Dam L, Dierickx D, Peccatori F, et al. Obstetrical complications and neonatal outcome in patients diagnosed with acute myeloid and acute lymphoblastic leukemia during pregnancy: Results from the International Network on Cancer, Infertility and Pregnancy (INCIP) study. Presented at the 2015 European Cancer Congress; Abstract 3205.

5. Sparano J, Gray R, Zujewski JA, et al. Prospective trial of endocrine therapy alone in patients with estrogen-receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry. Presented at the 2015 European Cancer Congress; Abstract 5BA.

6. Yates L, Knappskog S, Martincorena I, et al. The driver landscape of breast cancer metastasis and relapse. Presented at the 2015 European Cancer Congress; Abstract 1804.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content